|

Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery

RECRUITINGSponsored by Liaoning Cancer Hospital & Institute
Actively Recruiting
SponsorLiaoning Cancer Hospital & Institute
Started2024-03-21
Est. completion2025-09
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted

Summary

This study is a multicenter, prospective, and observational clinical study aimed at exploring whether the 3-year DFS in the Huaier group is not inferior to the control group receiving standard platinum dual-drug chemotherapy.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* 18 years old ≤ age ≤ 75, regardless of gender.
* Confirmed as non-small cell lung cancer by histopathology, with pathological staging of stage Ⅱ-ⅢA.
* Received radical R0 resection of lung cancer within 2 months before enrollment, and did not receive any postoperative adjuvant therapy or preoperative neoadjuvant therapy.
* ECOG(Eastern Cooperative Oncology Group)score:0-2.
* The patient voluntarily participated in the study, agreed to cooperate with the researcher for data collection, and signed an informed consent form.

Exclusion Criteria:

* Known to be allergic to the components of Huaier granules or avoid or use Huaier granules with caution (Huaier group).
* Those who have difficulty swallowing, complete or incomplete gastrointestinal obstruction, active gastrointestinal bleeding, perforation, and other causes of difficulty in taking oral medication.
* Non-small cell lung cancer patients who plan to receive targeted therapy, immunotherapy, chemotherapy combined with immunotherapy, radiotherapy, synchronous radiotherapy and chemotherapy during the study period.
* The patient has a history of other new malignant tumors within 5 years.
* The expected survival time of the patient is less than half a year.
* Surgical complications that have not recovered or are accompanied by severe infections after radical resection of lung cancer.
* Pregnant or lactating women or planned pregnancy preparation.
* The patient has received other traditional Chinese patent medicines and simple preparations with anti-tumor effect in the past one month (including but not limited to compound cantharidin capsule, cinobufagin capsule, Kangai injection, Brucea javanica injection, etc., the specific instructions shall prevail).
* The patient suffers from severe mental illness or other reasons that the researcher deems unsuitable to participate in this study.

Conditions3

CancerLung CancerNon Small Cell Lung Cancer

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.